# S100A alarmins and thymic stromal lymphopoietin (TSLP) regulation in severe asthma following bronchial thermoplasty

Pierre-Alexandre Gagnon, Martin Klein, John de Vos, Sabrina Biardel, Andréanne Côté, Krystelle Godbout, Michel Laviolette, Catherine Laprise, Said Assou, Jamila Chakir

<figure><img src="image_1.png" /></figure>

## To cite this version:

Pierre-Alexandre Gagnon, Martin Klein, John de Vos, Sabrina Biardel, Andréanne Côté, et al. S100A alarmins and thymic stromal lymphopoietin (TSLP) regulation in severe asthma following bronchial thermoplasty. Respiratory Research, 2023, 24 (1), pp.294. 10.1186/s12931-023-02604-1. hal-04964945

HAL Id: hal-04964945

https://hal.science/hal-04964945v1

Submitted on 25 Feb 2025

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
RESEARCH

Open Access

<figure><img src="image_3.png" /></figure>

Check for
updates

# S100A alarmins and thymic stromal lymphopoietin (TSLP) regulation in severe asthma following bronchial thermoplasty

Pierre-Alexandre Gagnon¹, Martin Klein¹, John De Vos², Sabrina Biardel¹, Andréanne Côté¹, Krystelle Godbout¹, Michel Laviolette¹, Catherine Laprise³, Said Assou² and Jamila Chakir¹*

**Abstract**

**Rationale** Severe asthma affects a small proportion of asthmatics but represents a significant healthcare challenge. Bronchial thermoplasty (BT) is an interventional treatment approach preconized for uncontrolled severe asthma after considering biologics therapy. It was showed that BT long-lastingly improves asthma control. These improvements seem to be related to the ability of BT to reduce airway smooth muscle remodeling, reduce the number of nerve fibers and to modulate bronchial epithelium integrity and behavior. Current evidence suggest that BT downregulates epithelial mucins expression, cytokine production and metabolic profile. Despite these observations, biological mechanisms explaining asthma control improvement post-BT are still not well understood.

**Objectives** To assess whether BT affects gene signatures in bronchial epithelial cells (BECs).

**Methods** In this study we evaluated the transcriptome of cultured bronchial epithelial cells (BECs) of severe asthmatics obtained pre- and post-BT treatment using microarrays. We further validated gene and protein expressions in BECs and in bronchial biopsies with immunohistochemistry pre- and post-BT treatment.

**Measurements and main results** Transcriptomics analysis revealed that a large portion of differentially expressed genes (DEG) was involved in anti-viral response, anti-microbial response and pathogen induced cytokine storm signaling pathway. S100A gene family stood out as five members of this family where consistently downregulated post-BT. Further validation revealed that S100A7, S100A8, S100A9 and their receptor (RAGE, TLR4, CD36) expressions were highly enriched in severe asthmatic BECs. Further, these S100A family members were downregulated at the gene and protein levels in BECs and in bronchial biopsies of severe asthmatics post-BT. TLR4 and CD36 protein expression were also reduced in BECs post-BT. Thymic stromal lymphopoietin (TSLP) and human β-defensin 2 (hBD2) were significantly decreased while no significant change was observed in IL-25 and IL-33.

**Conclusions** These data suggest that BT might improve asthma control by downregulating epithelial derived S100A family expression and related downstream signaling pathways.

**Keywords** Alarmin, Bronchial thermoplasty, Severe asthma

<footnote>*Correspondence:
Jamila Chakir
jamila.chakir@fmed.ulaval.ca
Full list of author information is available at the end of the article</footnote>
## Introduction

Asthma is a chronic inflammatory airway disease with increasing prevalence affecting over 300 million people worldwide. Severe asthma only affects approximately 5 to 10% of asthmatic patients. However, this proportion of asthmatics represents a significant healthcare challenge and contributes to up to half of direct asthma related costs. They respond poorly to standard asthma treatments and are more exposed to oral corticosteroids to achieve acceptable control with significant adverse outcomes associated with deterioration in quality of life [1].

According to current clinical standards, biologic treatment will be considered in such patients (GINA). Nevertheless, most of currently available biologics target T2 inflammation and are more effective in patients harboring features of such inflammation [2]. Even though, some patients might not be eligible or might not benefit from biologics therapy. For instance, a study evaluating response to mepolizumab (anti-IL5) of patients with high blood eosinophils reported cessation of treatment in about 14% of patients mainly because of failure to improve asthma control or based on clinician's decision [3].

An alternative to biologics therapy lays in bronchial thermoplasty (BT) which has been preconized in severe asthma patients unresponsive or ineligible to biologics, and therefore has been utilized in patients harboring features of T2-high and T2-low inflammation [2, 4, 5]. This approach consists in a single delivery of radiofrequency thermal energy in airways of 3–10 mm in diameter. Clinical trials showed that BT is safe and effective to reduce asthma exacerbations, emergency department visits and hospital admissions and improves quality of life for up to 10 years in patients with severe asthma treated with BT [6–10]. Observational and meta-analysis studies have further showed that BT induces clinical improvements comparable to biologics [11–13].

BT is the only treatment approach known to modulate airway remodeling, a characteristic asthma-related feature. BT induces airway smooth muscle (ASM) ablation occurring the first weeks after treatment and persisting for over a decade [14–20]. Subepithelial membrane thickening, and airway associated nerve fibers are similarly reduced [14–17, 20]. We and others have further showed that airway epithelium may be a target of BT. For instance, we showed that the structure of airway epithelium was improved following BT treatment and that airway epithelium regeneration in response to BT-induced epithelial injury decreased mucin expression, improved goblet cell metaplasia and regenerated the ciliated cell layer, providing a durable improvement of airway epithelium integrity [21, 22]. BT also seems to

modulate epithelial metabolic profile leading to a shift from a glycolysis-biased gene expression profile to an oxidative phosphorylation-based profile [23]. BT further seems to modulate the inflammatory profile of the airway epithelium [17, 21, 24].

Despite these observations, biological mechanisms explaining asthma control improvement following BT are still not well understood. This along with recent success of Tezepelumab targeting the epithelial derived thymic stromal lymphopoietin (TSLP) to improve asthma control regardless of T2 inflammation reemphasizes the cardinal role of the airway epithelium in asthma pathophysiology [25]. In this study, we assess whether BT affects gene signatures relevant to severe asthma pathophysiology in bronchial epithelial cells (BECs). To do so, we evaluate the transcriptome of BECs obtained pre- and post-BT treatment. We further validate protein expression of differentially expressed genes in bronchial biopsies pre- and post-BT treatment.

## Materials and methods

### Subjects' evaluation, BT procedure and biopsy processing

Twenty patients having suboptimal asthma control despite daily doses of at least 500 µg of fluticasone and at least 100 µg of salmeterol (or equivalents) were included in a clinical BT protocol at the Quebec Heart and Lung Institute asthma clinic. Bronchial biopsies were collected before BT and during a follow-up evaluation occurring at 12–48 months (mean 23 months) after treatment. Bronchial biopsies were also collected from non-smoking participants without asthma nor allergy. Further details about inclusion criteria, BT procedure and biopsy processing are provided elsewhere [13, 18]. The Ethics Committee at the Quebec Heart and Lung Institute approved the study. Participants were asked for consent to undergo bronchial biopsies and signed an informed consent form.

### BECs culture

BECs isolated from bronchial biopsies of healthy controls (n=7) and severe asthmatics pre-BT (n=12) and 12–18 months post-BT (n=6) were cultivated as we previously reported [26]. A representative immunofluorescence staining of epithelial cells with pan-cytokeratin antibody is showed in Additional file 4: Fig. S1. Cells were cultured until they reached over 90% confluence and were then collected in the appropriate lysis buffer and stored at –80 °C until needed. More details are provided in Additional file 1.
## Microarray analysis, data processing and bioinformatic analysis

Transcript levels data was generated using Clariom™S HT, human (Thermo Fisher Scientific, Massachusetts, USA). The expression pattern of the transcripts was analyzed using the robust multi-array average (RMA) algorithm and to construct a principal component analysis (PCA), the volcano plot and the heat-map. Different transcript levels with a significant *p*-value < 0.05 and fold changes of 2 or higher and of -2 or lower were retained. The gene ontology (GO) enrichment analysis, the pathways, and networks of differentially expressed transcripts between pre- and post-BT samples were analyzed using Ingenuity Pathway Analysis (IPA) software (IPA; Qiagen Inc., http://www.ingenuity.com). All our data are accessible at the gene expression Omnibus (GEO) repository (https://www.ncbi.nlm.nih.gov/geo) with the provisional accession series number GSE216617. More details are provided in Additional file 1.

## Real-time quantitative PCR analysis

One µg of total RNA was reverse transcribed and used for qRT-PCRs. Relative gene expression was normalized on GAPDH of healthy individuals' expression using ΔΔCt method [27]. More details are provided in Additional file 1.

## Protein extraction and Western blot

Twenty to 50 µg of total proteins was loaded on 12.5% acrylamide gel for SDS-PAGE and transferred on nitrocellulose membranes. Protein expression was measured by densitometry using Image Lab (Biorad, California, USA) and normalized to β-actin expression. More details are provided in Additional file 1.

## Immunohistochemistry (IHC)

Five µm sections of paraffin embedded bronchial biopsies were stained using the EXPOSE mouse and rabbit specific HRP/AEC detection IHC kit (Abcam, Cambridge, United-Kingdom) according to manufacturer's instructions. Positively stained epithelial area was measured as a percentage of total epithelial area using ImageJ (NIH, V1.53f51) as we previously reported [21]. More details are provided in Additional file 1.

## Statistical analysis

Statistical analysis for qRT-PCR, western blots and immunohistochemistry were conducted using GraphPad Prism Version 9.0 statistical software (GraphPad

Software). Data are expressed as mean ± standard error. Comparisons between groups when data were normally or not normally distributed were made with the Student's *t* test or the Mann-Whitney *U* test. For correlation analysis Pearson or Spearman tests were used. Significance was accepted at a value of *P* < 0.05.

## Results

### Subjects' clinical characteristics before and post-BT

Clinical characteristics of subjects are described in Table 1. Post-BD FEV₁ values did not change over time: 2.66 ± 0.18 L and 2.83 ± 0.19 L at baseline and at ≥ 12 months post-BT respectively. Four subjects were taking oral prednisone before BT and their doses decreased from a mean of 18.1 ± 5.5 to 6.3 ± 2.4 mg daily at long-term follow-up. The doses of inhaled corticosteroid (ICS) decreased from 1235 ± 175 µg before BT and 938 ± 166 µg of fluticasone or equivalent (p = 0.034) after-BT. The number of severe exacerbations decreased (p = 0.018) and the asthma control scoring system (ACSS) score, a local equivalent of ACQ [28], improved from 71 ± 4% to 88 ± 3% at long-term post-BT follow-up (p = 0.0004). Healthy controls were non-smokers, had no allergy or asthma or other inflammatory diseases. Their mean PC₂₀ was 107 ± 29 mg/ml and their mean FEV₁ was 3.50 ± 0.38 L; 93 ± 7 of % predicted.

<table><caption>**Table 1** Subjects' clinical characteristics</caption><thead><tr><th></th><th>Pre-BT</th><th>Post-BT</th><th>p-value</th></tr></thead><tbody><tr><td>Number of subjects</td><td>20</td><td>20</td><td></td></tr><tr><td>Months since BT*</td><td>—</td><td>23 (15)</td><td></td></tr><tr><td>Age (years)†</td><td>47 ± 2</td><td>49 ± 2</td><td></td></tr><tr><td>Sex (M/F)</td><td>8/12</td><td>8/12</td><td></td></tr><tr><td>Smoking status (no/ex/yes)</td><td>13/6/1</td><td>13/6/1</td><td></td></tr><tr><td>Atopy (no/yes)</td><td>6/14</td><td>6/14</td><td></td></tr><tr><td>Inhaled corticosteroid dose (µg)†,§</td><td>1275 ± 175</td><td>938 ± 166</td><td>0.035</td></tr><tr><td>Median (range)</td><td>1375 (0–3000)</td><td>750 (0–3000)</td><td></td></tr><tr><td>Long acting β₂-agonist (µg)†,||</td><td>114 ± 14</td><td>102 ± 13</td><td>0.45</td></tr><tr><td>Median (range)</td><td>100 (0–250)</td><td>100 (0–200)</td><td></td></tr><tr><td>Oral corticosteroids (n)</td><td>4 (7.5–30.0)</td><td>3 (5.0–10.0)</td><td>0.25</td></tr><tr><td>Omalizumab (n)</td><td>3</td><td>3</td><td>&gt; 0.99</td></tr><tr><td>Mepolizumab (n)</td><td>1</td><td>2</td><td>0.60</td></tr><tr><td>Montelukast (n)</td><td>9</td><td>8</td><td>&gt; 0.99</td></tr><tr><td>Post-BD FEV₁ (L)†</td><td>2.66 ± 0.18</td><td>2.83 ± 0.19</td><td>0.17</td></tr><tr><td>Count of severe exacerbations†</td><td>1 (0–10)</td><td>0 (0–2)</td><td>0.019</td></tr><tr><td>ACSS†</td><td>71 ± 4</td><td>88 ± 3</td><td>0.0004</td></tr></tbody></table>

*Mean (median)

† Mean ± standard error

‡ Median (range)

§ Fluticasone propionate or equivalent

|| Salmeterol or equivalent
Transcriptomics analysis

We compared by microarrays the transcriptome profile
of epithelial cells obtained from the same donors before
and after BT. We identified 421 genes that were differen-
tially expressed between pre- and post-BT with a twofold
change cut-off and p-value < 0.05 (Fig. 1A). Two hundred
twenty-two genes were downregulated and 199 upregu-
lated post-BT (Additional file 2: Table S3). The dendro-
gram of hierarchical clustering analysis showed that cells
before and post-BT treatment expressed specific molec-
ular signatures (Fig. 1B). Mapping of the samples in a
3-dimensional space using principal component analysis
(PCA) showed that BECs pre-BT were separated from
BECs post-BT based on their gene expression profile
(Additional file 5: Fig. S2A).

Heatmap plot based on the differentially expressed
genes (DEG) separated the effects of BT treatment
on cell samples and depicted overrepresentation of
genes involved in relevant pathways among the genes
differentially expressed pre- and post-BT. DEGs were
then functionally categorized using the IPA software.
A large portion of DEGs was involved in anti-viral
response, anti-microbial response and pathogen induced
cytokine storm signaling pathway (Fig. 1C). Further
analysis revealed that the interleukin (IL)-6,8,12,13,17,
toll-like receptor (TLR), interferon, p38 MAP kinase,
wound healing, inducible nitric oxide synthase (iNOS),
mammalian target of rapamycin (mTOR), production of
nitric oxide and reactive oxygen species in macrophages,
signal transducer and activator of transcription 3
(STAT3) and inflammasome signaling canonical
pathways were modulated post-BT (Additional file 5:
Fig. S2B and Additional file 3: Table S4). IPA software
was used to build an interaction network. Strikingly, the
interaction network showed that BECs pre- and post-BT
signatures were highly enriched in genes associated to
S100A alarmin family. These genes were downregulated
in post-BT (Fig. 1A, B). Remarkably, numerous genes
from S100A alarmin family such as S100A7, S100A8,
S100A9 were connected and formed a relevant network
(Fig. 1D). Interestingly, these candidate genes are
predicted downstream IL-17 signaling pathway and
related to antimicrobial response (Additional file 5: Fig.
S2C).

S100A family gene and protein validation

To validate these microarray data, qRT-PCR was per-
formed on an independent collection of BECs samples
obtained from severe asthma patients pre- and post-BT
treatment. We first documented baseline expression of
S100A7, S100A8 and S100A9 genes in severe asthma and
compared to BECs obtained from healthy controls. Fig-
ure 2A shows that S100A7, S100A8 and S100A9 genes
were highly expressed in BECs of severe asthmatics in
comparison to those of healthy controls. This expression
is on average fivefold for S100A7 (p=0.01), 4.8-fold for
S100A8 (p=0.008) and threefold for S100A9 (p=0.01)
higher in BECs from severe asthmatics in comparison
to healthy control. Post-BT data showed a significant
decrease compared to pre-BT values in S100A7 (four-
fold decrease, p=0.03), and S100A8 (3.6-fold decrease,
p=0.05). The decrease is less marked for S100A9 gene
expression (1.6-fold decrease, p=0.09) (Fig. 2B).

At protein level, expression of all three S100 family
proteins was highly upregulated in BECs of severe
asthmatic patients in comparison to healthy controls
(p=0.03, p=0.01, p=0.02 respectively). BT treatment
reduced protein levels of S100A7, S100A8 (p=0.05,
p=0.03) and did not affect S100A9 in comparison to
pre-BT values (Fig. 4B).

S100A family epithelial in bronchial biopsies of severe asthmatics

S100A7, S100A8 and S100A9 expression in bronchial
tissues were evaluated by immunostaining of bron-
chial biopsies obtained pre- and post-BT treatment.
Figure 3A shows representative immunostaining for
S100A7, S100A8 and S100A9 in bronchial biopsies with
high expression pre-BT and reduced expression post-BT.
Mean epithelial positive area of each S100A decreased
post-BT: 19% to 11.8% for S100A7 (p-value = 0.048); 9.8%
to 6% for S100A8 (p-value = 0.004) and 9.3% to 4% for
S100A9 (p-value = 0.012) (Fig. 3B).

The decrease of S100A7 and S100A9 epithelial
expressions following BT correlated with their pre-BT
epithelial levels of expression (p-values = 0.0006
and < 0.0001, respectively). A similar tendency towards
correlation was observed for S100A8 (p-value = 0.08

(See figure on next page.)

**Fig. 1** Transcriptomic analysis of BECs of severe asthmatics pre- and post-BT measured using microarray. **A** Volcano plot showing the distribution of transcript expression P values and fold changes. All transcripts were tested using the transcriptome analysis console (TAC) software. **B** Heat map. The molecular signatures pre-BT and post-BT were visualized by hierarchical clustering based on the differential transcripts' expression. **C** Interaction network constructed using the ingenuity pathway analysis software. Nodes shaded in pink or red represent genes that are upregulated, and blue nodes are downregulated post-BT. A solid line represents a direct interaction and a dotted line an indirect interaction. **D** Several S100A family genes were interconnected in the same network in the post-BT signature. The color intensity indicates the degrees of up-regulation or down-regulation
<figure><img src="image_4.png" /><figcaption>Fig. 1 (See legend on previous page.)</figcaption></figure>
<figure><img src="image_5.png" /><figcaption>**Fig. 2** Validation of S100A family gene and protein expressions in BECs of non-asthmatic-controls and severe asthmatics pre- and post-BT. **A** Bar plots representing qPCR data. **B** Bar plot representing Western Blot data on top with representative blots below</figcaption></figure>
<figure><img src="image_6.png" /><figcaption>**Fig. 3** S100A family protein expressions in tissues of severe asthmatics pre- and post-BT. A Representative immunostainings for S100A family proteins. B Graphical representations of immunostaining quantification. S100A family protein expression is represented as % of epithelial area</figcaption></figure>

(Additional file 6: Fig. S3A). Epithelial expression of S100A7 and S100A8 pre-BT negatively correlated with ACCS score (r=-0.6; p-value=0.03 and r=-0.7; p-value=0.006 respectively) suggesting that higher expression of these proteins might indicate a poorer asthma control (Additional file 6: Fig. S3B).

## S100A family receptors and other alarmins

We found by Western Blot experiments that S100A family receptors were highly expressed in severe asthmatic BECs. The expression is on average of 2.6-fold for RAGE (p=0.004), 1.8-fold for TLR4 (p=0.005) and 2.6-fold for CD36 (p<0.001). We further found a significant decrease in TLR4 and CD36 expression post-BT (p-values of 0.001

and 0.01 respectively) and no change in RAGE expression (Fig. 4).

We also evaluated by qRT-PCR the effect of BT on the expression of *IL-25*, *IL-33*, *TSLP* and *hBD2*; typical asthma-related alarmins or antimicrobial peptides in BECs. We observed a significant decrease in *TSLP* (p=0.02) and *hBD2* (p=0.02), while no significant change was observed in *IL-25* and *IL-33* (Additional file 7: Fig. S4).

## Discussion

This study showed that transcriptomic analysis of BECs identified a downregulation of inflammation with the modulation of asthma-related relevant canonical pathways such as IL-13 and S100A alarmins
<figure><img src="image_7.png" /></figure>

<figure><img src="image_8.png" /><figcaption>**Fig. 4** Expression of S100A family receptors in BECs. Western Blots of selected S100A family receptors (RAGE, TLR4, CD36) on top with associated graphical representations below</figcaption></figure>

downstream of IL-17 signaling as potential gene family regulated by BT treatment. We found that BT downregulated *S100A7*, *S100A8* and *S100A9* gene expressions of cultured BECs. This downregulation was further validated at gene and protein levels in BECs and bronchial biopsies of the same patients. Moreover, this downregulation of S100A family 1-year or more post-BT paralleled the reduction of asthma exacerbations and better asthma control. We showed that S100A family receptors; RAGE, TLR4 and CD36, are upregulated in severe asthmatic BECs and that BT induces a downregulation of TLR4 and CD36 expression. Finally, gene expressions of *TSLP* and *hBD2*, are downregulated post-BT in BECs.

The S100A family proteins of interest here are immunomodulatory, antioxidant and calcium/zinc binding proteins mainly expressed by leucocytes of myeloid origin (neutrophils, monocytes) and/or

epithelial cells (basal respiratory cells, keratinocytes) [29, 30]. Higher expressions of S100A8, S100A9 and/or calprotectin (S100A8/A9 complex) were reported in sputum, bronchoalveolar lavage (BAL) and serum of asthmatic patients when compared to healthy controls [31–37]. Decaesteker et al. reported that there was no difference in serum calprotectin levels between asthmatics patients with high sputum eosinophilia and patients with sputum neutrophilia. However, severe asthmatic patients seemed to have higher calprotectin levels than healthy controls. The authors suggest that calprotectin may be a marker of disease severity rather than a marker for specific inflammatory subtypes [34]. Lee and colleagues found that S100A9 levels were higher in sputum from patients with severe uncontrolled asthma with neutrophilic inflammation than in sputum from eosinophilic and paucigranulocytic groups [37]. Together, these studies show that the role of S100A
family proteins may vary according to the inflammatory context in the asthmatic airways. The role of S100A family is not clear in T2-high setting as it may favor or regulate T2 inflammation depending on the context [38–40]. Nevertheless, S100A molecules appear of cardinal importance in T17-high setting [33, 35, 37, 41]. Thus, BT-induced downregulation of S100A family proteins could imply modulation of more than one inflammatory pathway further supporting its ability to act on broader pathophysiological mechanisms rather than a specific endotype. Östling et al. reported an enrichment of canonical pathways associated to T17 biology (Role of IL-17A in psoriasis, role of IL-17F in allergic inflammatory airway diseases), TLR signaling, iNOS signaling and inflammasome in bronchial epithelial brushings of a subset of asthmatics. This was characterized by an upregulation of *S100A8* and *S100A9* amongst other genes [41]. Therefore, there are similarities in the gene signature identified by Östling et al. in a subset of asthmatics and the gene signature we identified to be modulated by BT in our population. S100A7 is upregulated in response to IL-22, a Th17 cytokine in BECs [42]. S100A8 and S100A9 can promote mucus hypersecretion typical of asthma in BECs, which is consistent with our previously published works documenting reduced MUC5AC post-BT along with IL-13+ cells in bronchial biopsies collected from a similar cohort [21, 43]. Further, we showed that S100A7 and S100A8 expressions might be indicators of disease severity as measured by lower ACSS score and that patients with a greater S100A protein decrease had more of these proteins in their airway tissues prior to BT. This goes along with the lines of studies reporting higher S100A9 or calprotectin expression in serum with lower FEV₁/FVC ratio, increased airway hyper-reactivity, or uncontrolled asthma [32, 34, 35]. Our results are consistent with current literature.

S100A family proteins are ligands of receptor for advanced glycation end products (RAGE) and of toll-like receptor 4 (TLR4). They are believed to promote inflammation through these pathways [30]. A house dust mite (HDM) sensitized RAGE-KO mouse model showed that airway structural cell expression of RAGE contributes to IL-33 accumulation and further ILC2 accumulation [44]. In other assays conducted in mice, calprotectin secretion was largely dependent upon RAGE signaling when stimulated with T2 cytokines (IL-4, 5 and 13) [45]. TLR4 signaling has also been shown to contribute to T2 inflammation. By selectively inactivating TLR4 on airway structural cells, a study group showed that airway epithelium of HDM stimulated mice produced more T2 alarmins (e.g. IL-25, IL-33, TSLP) and contributed to dendritic cells activation if

they expressed TLR4 [46]. Exposition of normal BECs to *Alternaria* allergens induced TSLP and IL-25 secretion. Adding calprotectin further enhanced secretions of these cytokines [38]. A study using an asthma murine model challenged with *A. fumigatus* mixed with OVA showed that neutralizing antibodies against S100A8 and S100A9 alleviated airway inflammation and eosinophil recruitment [39].

On the other hand, some studies have reported beneficial effects for S100A8 and/or S100A9 expressions. For instance, a study using a calprotectin-deficient mouse model sensitized to *Alternaria alternata* showed that allergen exposition did increase S100A9 expression in the lung of wild type mice though the deficient mice displayed a worsened T2 inflammation and bronchial hyper-responsiveness [40]. Administering recombinant S100A8 to ovalbumin sensitized rats reduced pulmonary resistance and bronchial hyper-responsiveness. Further, in vitro administration of recombinant S100A8 on isolated tracheal rings from the same rat model reduced airway smooth muscle contractility [47].

CD36 is a scavenger receptor interacting with a broad range of ligands such as thrombospondin, collagen, long chain fatty acids and bacterial diacylated lipopeptides [48]. CD36 can associate with TLR2/6 or TLR4/6 complexes and favor immune response in context of infection or sterile inflammation [49, 50]. Further, calprotectin-arachidonate complex are recognized by CD36 receptor which could further favor arachidonate uptake and eicosanoids production by epithelial cells [51]. We observed a reduction of S100A family and of two of its receptors (TLR4 and CD36) in BECs post-BT; suggesting that BT benefits might be related to the reduced signaling pathways involving S100A family, TLR4 and CD36. Though, the role of S100A family proteins in TLR and CD36 signaling in the context of severe asthma remains unclear and needs further investigation.

We investigated the effect of BT on the epithelial expression of the trio of alarmins *IL-25* and *IL-33* and *TSLP* which are well documented in asthma as well as on *hBD2*, an antimicrobial peptide [52, 53]. Interestingly, we found a downregulation of *TSLP* and of *hBD2* in parallel to *S100A* family gene expressions. Though TSLP was classically associated to eosinophilic inflammation, it was more recently shown to be involved in non-eosinophilic inflammation and remodeling [54]. The results of recent clinical trials support this idea. Indeed, treatment with anti-TSLP reduced the exacerbation rate of patients with and without features of eosinophilic inflammation [25]. Considering that S100A8, S100A9, TSLP and hBD2 can be elicited by stimuli of various origins (allergens, pollutants, bacteria, cytokines), our results suggest
that BT might act on mediators involved in broader pathophysiological mechanisms rather than targeting a specific endotype [38, 53, 54]. This is supported by other studies reporting better asthma control post-BT in patients with and without T2 inflammation [4, 5]. This might be a downstream effect of the BT-induced renewal of the epithelium and subsequent improved integrity [21, 22]. The later might improve the ability of the epithelium to orchestrate a proper response to external stimuli.

Severe asthma is associated with greater ASM mass with greater CXCL8 and eotaxin ASM expression [55, 56]. ASM can further stimulate the epithelium to produce various cytokines [57]. Many studies showed that BT induced long lasting ASM ablation [14–20]. It is not clear to which mechanism(s) S100A family downregulation may be attributed. It might be related to improvement in epithelial integrity leading to proper response to external stimuli and reduced production of alarmins and their receptors; ASM ablation reducing the need for contractility modulating proteins or ASM ablation leading to reduced production of chemokines and modulation of inflammation resulting in proper epithelial priming.

Taken together our results support the idea that the S100A family proteins and their related signaling pathways play a relevant role in severe asthma pathophysiology and that a reduced expression might be an indicator of response to BT treatment. They also support that BT, through its effects on airway structural cells, contributes to modulate local innate immune response and inflammation. The nature of BT treatment (heat delivery) and current evidence support that its beneficial effects may not be solely attributable to ASM ablation. For instance, we previously showed that BT induced the renewal of the ciliated cell layer, lastingly increased the number of basal progenitor cells and reduced the production of MUC5AC. This is accompanied by an increase in proliferating epithelial cells in the first two months [4, 21, 58] post-treatment while this goes back to basal level more than 1 year post treatment [21]. Further, in vitro experiments exposing epithelial cell cultures to heat as a proxy of BT showed that it may increase proliferation of epithelial cells and modulate their expression of differentiation markers [58, 59]. While in vitro heat treatment may be useful in assessing the effect of BT on epithelial cells, this only captures acute effect of heat which might not reflect long-lasting disease modifying mechanisms. We therefore believe that the current study assessing effect of BT on S100A family is more likely related to lasting clinical benefits.

Though the exact role of S100A family proteins in asthma pathophysiology is still not clear, higher

expression is associated with disease. Further studies are needed to better understand the role of S100A family proteins and their receptors in relation to asthma pathophysiology which might be relevant in treatment monitoring.

Western Blots of selected S100A family receptors (RAGE, TLR4, CD36) on top with associated graphical representations below.

## Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12931-023-02604-1.

**Additional file 1:** Supplementary method.

**Additional file 2: Table S3.** Down and up regulated genes in BECs post-BT.

**Additional file 3: Table S4.** Canonical pathways of genes modulated by BT.

**Additional file 4: Figure S1.** Purity validation of BEC. Shows a representative brightfield image of BEC culture (top) and a representative immunofluorescence for DAPI (blue) and pan-cytokeratin (green) (bottom).

**Additional file 5: Figure S2.** Transcriptomic analysis and canonical pathways of differentially expressed genes in BECs pre- and post-BT. **A.** Principal component analysis (PCA) 3-dimensional plots representing the transcript expression patterns of the different samples (pre- and post-BT: blue dots and red dots respectively). Each dot represents a sample showing two distinct transcript expression profiles. **B.** The main canonical pathways enriched in samples modulated by BT. **C.** Representation of some S100A genes in the IL-17 signaling pathway. Genes shown in green are down-regulated post-BT.

**Additional file 6: Figure S3.** Correlation analysis of S100A family proteins in tissues. **A.** Correlations of epithelial S100A family protein expressions with BT-induced expression changes. Y axis displays the expression differences post-BT (expression post-BT minus expression pre-BT). **B.** Correlations of epithelial S100A family proteins expression with ACSS score. ACSS is a local equivalent to ACQ.

**Additional file 7: Figure S4.** Gene expression of IL-25 and IL-33, TSLP and hBD2 in BECs of severe asthmatic patients pre- and post-BT. TSLP and hBD2 gene expressions decreased post-BT while no significant change was observed for IL-25 and IL-33.

## Acknowledgements

The authors thank the staff at the Quebec Respiratory Health research Network Biobank IUCPQ site (www.tissuebank.ca), Dr. Anne-Marie Madore from UQAC and Dr. Olivier Boucherat from IUCPQ-UL for their valuable assistance.

## Author contributions

JC and ML conceived and designed the experiments. Microarray experiments were conducted in collaboration with CL who revised the manuscript. Analysis of transcriptomics data was conducted by SA and JV, PAG conducted the validation experiments and related analysis (quantitative PCR, Western Blot, Immunohistochemistry). PAG, SA and JC wrote the manuscript. MK participated in the validation experiments and revised the manuscript. SB processed the tissues and collected the clinical data. AC, KG and ML insured clinical follow-up of participants and ML performed bronchial thermoplasty.

## Funding

P.A.G. received Louise Côté scholarship of Laval University and scholarship complement from Quebec Respiratory Health Research Network (QRHN). M.K. received a scholarship complement from Quebec Respiratory Health Research Network (QRHN). J.C. received grants from Fonds sur les maladies respiratoires
J-D-Bégin P-H-Lavoie and Quebec Respiratory Health Research Network (QRHN).

## Availability of data and materials

Transcriptomic data are accessible at the gene expression Omnibus (GEO) repository (https://www.ncbi.nlm.nih.gov/geo) with the provisional accession series number GSE216617.

## Declarations

### Ethics approval and consent to participate

The Ethics Committee at the Quebec Heart and Lung Institute which evaluated the project in accordance to "Tri-Council policy statement: ethical conduct for research involving human" and approved the study (CER 22279). Participants were asked for consent to undergo bronchial biopsies and signed an informed consent form.

### Competing interests

A.C. received: a grant from GSK for an investigator-initiated study; consulting fees from Astra Zeneca; speaker fees from Astra Zeneca, GSK, Valeo pharma, Sanofi and Covis; participation on advisory board for Astras Zeneca, GSK, Valeo pharma, Sanofi and Regeneron. K.G. received: speaker fees from Astra Zeneca, Boehringer, Covis, GSK, Novartis and Valeo pharma; participation on advisory board for Astra Zeneca, Covis, GSK, Sanofi, Valeo pharma and TEVA.

### Author details

¹Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval (IUCPQ-UL), 2725 Chemin Sainte-Foy, Québec, QC G1V 4G5, Canada. ²IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, France. ³Département des Sciences Fondamentales, Université du Québec à Chicoutimi (UQAC), Saguenay, QC, Canada.

Received: 10 August 2023 Accepted: 13 November 2023

Published online: 23 November 2023

## References

1. Cote A, Godbout K, Boulet LP. The management of severe asthma in 2020. Biochem Pharmacol. 2020;179: 114112.

2. Global initiative for asthma (GINA). Global Strategy for Asthma Management and Prevention. 2022. www.ginaasthma.org.

3. Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, Harrington J, Hew M, Kritikos V, Radhakrishna N, Bardin P, Peters M, Reynolds PN, Upham JW, Baraket M, Bowler S, Bowden J, Chien J, Chung LP, Grainge C, Jenkins C, Katsoulotos GP, Lee J, McDonald VM, Reddel HK, Rimmer J, Wark PAB, Gibson PG. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020;55:1902420.

4. Papakonstantinou E, Koletsa T, Zhou L, Fang L, Roth M, Karakioulaki M, Savic S, Grize L, Tamm M, Stolz D. Bronchial thermoplasty in asthma: an exploratory histopathological evaluation in distinct asthma endotypes/phenotypes. Respir Res. 2021;22:186.

5. Facciolongo N, Bonacini M, Galeone C, Ruggiero P, Menzella F, Ghidoni G, Piro R, Scelfo C, Catellani C, Zerbini A, Croci S. Bronchial thermoplasty in severe asthma: a real-world study on efficacy and gene profiling. Allergy Asthma Clin Immunol. 2022;18:39.

6. Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, Olivenstein R, Pavord ID, McCormack D, Chaudhuri R, Miller JD, Laviolette M. Asthma control during the year after bronchial thermoplasty. N Engl J Med. 2007;356:1327-37.

7. Pavord ID, Cox G, Thomson NC, Rubin AS, Corris PA, Niven RM, Chung KF, Laviolette M. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med. 2007;176:1185-91.

8. Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade LM, Shah PL, Fiss E, Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Duhamel DR, McEvoy C, Barbers R, Ten Hacken NH, Wechsler ME, Holmes M, Phillips MJ, Erzurum S, Lunn W, Israel E, Jarjour N, Kraft M, Shargill NS, Quiring J, Berry SM, Cox G. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181:116-24.

9. Chupp G, Laviolette M, Cohn L, McEvoy C, Bansal S, Shifren A, Khatri S, Grubb GM, McMullen E, Strauven R, Kline JN. Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studies. Eur Respir J. 2017;50:1700017.

10. Chaudhuri R, Rubin A, Sumino K, Lapa ESJR, Niven R, Siddiqui S, Klooster K, McEvoy C, Shah PL, Simoff M, Khatri S, Barbers R, Mark Grubb G, McMullen EA, Olson JL, Laviolette M. Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials. Lancet Respir Med. 2021;9(5):457-66.

11. Menzella F, Fontana M, Galeone C, D'Amato M, Canonica GW, Ghidoni G, Capobelli S, Scelfo C, Simonazzi A, Catellani C, Ruggiero P, Facciolongo N. A real-world evaluation of clinical outcomes of biologicals and bronchial thermoplasty for severe refractory asthma (BIOTERM). J Asthma Allergy. 2021;14:1019-31.

12. Langton D, Sha J, Guo S, Sharp J, Banks C, Wang W, Plummer V, Thien F. Bronchial thermoplasty versus mepolizumab: comparison of outcomes in a severe asthma clinic. Respiriology. 2020;25:1243.

13. Fong KY, Zhao JJ, Syn NL, Nair P, Chan YH, Lee P. Comparing bronchial thermoplasty with biologicals for severe asthma: systematic review and network meta-analysis. Respir Med. 2023;216: 107302.

14. Chakir J, Haj-Salem I, Gras D, Joubert P, Beaudoin EL, Biardel S, Lampron N, Martel S, Chanez P, Boulet LP, Laviolette M. Effects of bronchial thermoplasty on airway smooth muscle and collagen deposition in asthma. Ann Am Thoracic Society. 2015;12:1612-8.

15. Haj Salem I, Boulet LP, Biardel S, Lampron N, Martel S, Laviolette M, Chakir J. Long-term effects of bronchial thermoplasty on airway smooth muscle and reticular basement membrane thickness in severe asthma. Ann Am Thorac Soc. 2016;13:1426-8.

16. Pretolani M, Bergqvist A, Thabut G, Dombret MC, Knapp D, Hamidi F, Alavoine L, Taille C, Chanez P, Erjefalt JS, Aubier M. Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: clinical and histopathologic correlations. J Allergy Clin Immunol. 2017;139:1176-85.

17. Ladjemi MZ, Di Candia L, Heddebaut N, Techoueyres C, Airaud E, Soussan D, Dombret MC, Hamidi F, Guillou N, Mordant P, Castier Y, Letuve S, Taille C, Aubier M, Pretolani M. Clinical and histopathologic predictors of therapeutic response to bronchial thermoplasty in severe refractory asthma. J Allergy Clin Immunol. 2021;48:1227.

18. Facciolongo N, Di Stefano A, Pietrini V, Galeone C, Bellanova F, Menzella F, Scichilone N, Piro R, Bajocchi GL, Balbi B, Agostini L, Salsi PP, Formisano D, Lusuardi M. Nerve ablation after bronchial thermoplasty and sustained improvement in severe asthma. BMC Pulm Med. 2018;18:29.

19. Gagnon PA, Cote A, Klein M, Biardel S, Laviolette M, Godbout K, Bosse Y, Chakir J. The reduction of airway smooth muscle by bronchial thermoplasty stands the test of time. ERJ Open Res. 2023;9:00024.

20. Jendzjowsky N, Laing A, Malig M, Matyas J, de Heuvel E, Dumonceaux C, Dumoulin E, Tremblay A, Leigh R, Chee A, Kelly MM. Long-term modulation of airway remodelling in severe asthma following bronchial thermoplasty. Eur Respir J. 2022;59:2100622.

21. Haj Salem I, Gras D, Joubert P, Boulet LP, Lampron N, Martel S, Godbout K, Chanez P, Laviolette M, Chakir J. Persistent reduction of mucin production after bronchial thermoplasty in severe asthma. Am J Respir Crit Care Med. 2019;199:536-8.

22. Chernyavsky IL, Russell RJ, Saunders RM, Morris GE, Berair R, Singapuri A, Chachi L, Mansur AH, Howarth PH, Dennison P, Chaudhuri R, Bicknell S, Rose F, Siddiqui S, Brook BS, Brightling CE. In vitro, in silico and in vivo study challenges the impact of bronchial thermoplasty on acute airway smooth muscle mass loss. Eur Respir J. 2018;51:1701680.

23. Ravi A, Goorsenberg AWM, Dijkhuis A, Dierdorp BS, Dekker T, van Weeghel M, Sabogal Pineros YS, Shah PL, Ten Hacken NHT, Annema JT, Sterk PJ, Vaz FM, Bonta PI, Lutter R. Metabolic differences between bronchial epithelium from healthy individuals and patients with asthma and the effect of bronchial thermoplasty. J Allergy Clin Immunol. 2021;148:1236.

24. Wijsman PC, Goorsenberg AWM, Ravi A, d'Hooghe JNS, Dierdorp BS, Dekker T, van Schaik C, Ten Hacken NHT, Shah PL, Weersink EJM, Bel EH, Annema JT, Lutter R, Bonta PI. Airway inflammation before and
after bronchial thermoplasty in severe asthma. J Asthma Allergy.
2022;15:1783-94.

25. Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, Ambrose CS, Hellqvist A, Roseti SL, Molfino NA, Llanos JP, Martin N, Bowen K, Griffiths JM, Parnes JR, Colice G. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208:13-24.

26. Semlali A, Jacques E, Plante S, Biardel S, Milot J, Laviolette M, Boulet LP, Chakir J. TGF-beta suppresses EGF-induced MAPK signaling and prolifera-
tion in asthmatic epithelial cells. Am J Respir Cell Mol Biol. 2008;38:202-8.

27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-8.

28. Boulet LP, Boulet V, Milot J. How should we quantify asthma control? A proposal. Chest. 2002;122:2217-23.

29. Sattar Z, Lora A, Jundi B, Railwah C, Geraghty P. The S100 protein family as players and therapeutic targets in pulmonary diseases. Pulm Med. 2021;2021:5488591.

30. Gonzalez LL, Garrie K, Turner MD. Role of S100 proteins in health and disease. Biochim Biophys Acta. 2020;1867:118677.

31. Huang X, Tan X, Liang Y, Hou C, Qu D, Li M, Huang Q. Differential DAMP release was observed in the sputum of COPD, asthma and asthma-COPD overlap (ACO) patients. Sci Rep. 2019;9:19241.

32. Lee YG, Hong J, Lee PH, Lee J, Park SW, Kim D, Jang AS. Serum calprotectin is a potential marker in patients with asthma. J Korean Med Sci. 2020;35:e362.

33. Lee TH, Chang HS, Bae DJ, Song HJ, Kim MS, Park JS, Jun JA, Lee SY, Uh ST, Kim SH, Park CS. Role of S100A9 in the development of neutrophilic inflammation in asthmatics and in a murine model. Clin Immunol. 2017;183:158-66.

34. Decaesteker T, Bos S, Lorent N, Everaerts S, Vanoirbeek J, Bullens D, Dupont LJ. Elevated serum calprotectin (S100A8/A9) in patients with severe asthma. Journal Asthma. 2021;59:1-6.

35. Quoc QL, Choi Y, Thi Bich TC, Yang EM, Shin YS, Park HS. S100A9 in adult asthmatic patients: a biomarker for neutrophilic asthma. Exp Mol Med. 2021;53:1170-9.

36. Kim DH, Choi E, Lee JS, Lee NR, Baek SY, Gu A, Kim DH, Kim IS. House dust mite allergen regulates constitutive apoptosis of normal and asthmatic neutrophils via toll-like receptor 4. PLoS ONE. 2015;10: e0125983.

37. Lee TH, Jang AS, Park JS, Kim TH, Choi YS, Shin HR, Park SW, Uh ST, Choi JS, Kim YH, Kim Y, Kim S, Chung IY, Jeong SH, Park CS. Elevation of S100 calcium binding protein A9 in sputum of neutrophilic inflam-
mation in severe uncontrolled asthma. Ann Allergy Asthma Immunol. 2013;111(268-275): e261.

38. Kato T, Kouzaki H, Matsumoto K, Hosoi J, Shimizu T. The effect of calpro-
tectin on TSLP and IL-25 production from airway epithelial cells. Allergol
Int. 2017;66:281-9.

39. Greenlee KJ, Corry DB, Engler DA, Matsunami RK, Tessier P, Cook RG, Werb Z, Kheradmand F. Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflam-
mation. J Immunol. 2006;177:7312-21.

40. Palmer LD, Maloney KN, Boyd KL, Goleniewska AK, Toki S, Maxwell CN, Chazin WJ, Peebles RS Jr, Newcomb DC, Kaar EP. The innate immune pro-
tein S100A9 protects from T-Helper cell type 2-mediated allergic airway
inflammation. Am J Respir Cell Mol Biol. 2019;61:459-68.

41. Ostling J, van Geest M, Schofield JPR, Jevnikar Z, Wilson S, Ward J, Lutter R, Shaw DE, Bakke PS, Caruso M, Dahlen SE, Fowler SJ, Horvath I, Krug N, Montuschi P, Sanak M, Sandstrom T, Sun K, Pandis I, Auffray C, Sousa AR, Guo Y, Adcock IM, Howarth P, Chung KF, Bigler J, Sterk PJ, Skipp PJ, Djukanovic R, Vaarala O. IL-17-high asthma with features of a psoriasis immunophenotype. J Allergy Clin Immunol. 2019;144:1198-213.

42. Pennino D, Bhavsar PK, Effner R, Avitabile S, Venn P, Quaranta M, Marzaioli V, Cifuentes L, Durham SR, Cavani A, Eyerich K, Chung KF, Schmidt-Weber CB, Eyerich S. IL-22 suppresses IFN-gamma-mediated lung inflammation in asthmatic patients. J Allergy Clin Immunol. 2013;131:562-70.

43. Kang JH, Hwang SM, Chung IY. S100A8, S100A9 and S100A12 activate airway epithelial cells to produce MUC5AC via extracellular signal-regulated kinase and nuclear factor-kappaB pathways. Immunology. 2015;144:79-90.

44. Oczypok EA, Milutinovic PS, Alcorn JF, Khare A, Crum LT, Manni ML, Epperly MW, Pawluk AM, Ray A, Oury TD. Pulmonary receptor for

advanced glycation end-products promotes asthma pathogenesis
through IL-33 and accumulation of group 2 innate lymphoid cells. J
Allergy Clin Immunol. 2015;136(747-756): e744.

45. Perkins TN, Oczypok EA, Dutz RE, Donnell ML, Myerburg MM, Oury TD. The receptor for advanced glycation end products is a critical mediator of type 2 cytokine signaling in the lungs. J Allergy Clin Immunol. 2019;144(796-808): e712.

46. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med. 2009;15:410-6.

47. Xu YD, Wang Y, Yin LM, Park GH, Ulloa L, Yang YQ. S100A8 protein attenuates airway hyperresponsiveness by suppressing the contraction of airway smooth muscle. Biochem Biophys Res Commun. 2017;484:184-8.

48. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immu-
nity, metabolism, angiogenesis, and behavior. Sci Signal. 2009;2: re3.

49. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT, Moore KJ. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010;11:155-61.

50. Triantafilou M, Gamper FG, Haston RM, Mouratis MA, Morath S, Hartung T, Triantafilou K. Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J Biol Chem. 2006;281:31002-11.

51. Kerkhoff C, Sorg C, Tandon NN, Nacken W. Interaction of S100A8/S100A9-arachidonic acid complexes with the scavenger receptor CD36 may facilitate fatty acid uptake by endothelial cells. Biochemistry. 2001;40:241-8.

52. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16:45-56.

53. Niyonsaba F, Kiatsurayanon C, Ogawa H. The role of human beta-defensins in allergic diseases. Clin Exp Allergy. 2016;46:1522-30.

54. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24:777-92.

55. Pepe C, Foley S, Shannon J, Lemiere C, Olivenstein R, Ernst P, Ludwig MS, Martin JG, Hamid Q. Differences in airway remodeling between subjects with severe and moderate asthma. J Allergy Clin Immunol. 2005;116:544-9.

56. Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M. Airway struc-
tural alterations selectively associated with severe asthma. Am J Respir
Crit Care Med. 2003;167:1360-8.

57. Osei ET, Booth S, Hackett TL. What have in vitro co-culture models taught us about the contribution of epithelial-mesenchymal interactions to airway inflammation and remodeling in asthma? Cells. 2020;9:1694.

58. Fang L, Li J, Papakonstantinou E, Karakioulaki M, Sun Q, Schumann D, Tamm M, Stolz D, Roth M. Secreted heat shock proteins control airway remodeling: Evidence from bronchial thermoplasty. J Allergy Clin Immunol. 2021;148:1249.

59. Sun QZ, Fang L, Roth M, Tang XM, Papakonstantinou E, Zhai WQ, Louis R, Heinen V, Schleich FN, Lu SM, Savic S, Tamm M, Stolz D. Bronchial thermoplasty decreases airway remodelling by blocking epithelium-derived heat shock protein-60 secretion and protein arginine methyltransferase-1 in fibroblasts. Eur Resp J. 2019;54:1900300.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.